Moderna recently dosed the first participant in a Phase 1 study of its mRNA vaccine, mRNA-1189, for Epstein-Barr Virus (EBV).
The Eclipse study will enroll nearly 270 participants 18 to 30 years of...
FDA recently expanded the emergency use authorization for the Pfizer-BioNTech COVID-19 vaccine booster to include individuals 12 years of age and older.
The authorization follows two months after the...
Johnson & Johnson recently announced that its COVID-19 vaccine, Ad26.COV2.S, was 85 percent effective against coronavirus-related hospitalization in a Phase 3b study.
The South African Medical...
Pfizer and BioNTech recently announced that they will amend the clinical study evaluating the safety, tolerability, and immunogenicity of their COVID-19 vaccine in children.
The Phase 1/2/3 trial...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently issued positive opinion of Johnson & Johnson’s COVID-19 vaccine booster for...
Johnson & Johnson recently announced preliminary results from an independent study, which showed that a booster shot of its COVID-19 vaccine increased both antibody and T-cell responses.
In the...
The Strategic Advisory Group of Experts on Immunization (SAGE) for the World Health Organization (WHO) recently supported using Johnson & Johnson’s COVID-19 vaccine booster shot in...
GSK recently welcomed the decision of the Gavi Board to fund the procurement and introduction of malaria vaccines into routine child immunization programs in eligible countries.
GSK developed its...
Pfizer and BioNTech recently announced that their COVID-19 vaccine neutralized the SARS-CoV-2 Omicron variant after three doses.
A month after receiving the booster vaccination, sera obtained...
Johnson & Johnson recently announced a potential licensing agreement for its COVID-19 vaccine with Aspen SA Operations (Pty) Ltd, based in South Africa.
The companies will work towards a...
FDA is working with federal partners and regulators to address potential impacts of the new Omicron variant and urges everyone to receive COVID-19 vaccinations or booster shots, according to an...
Moderna recently dosed the first participant in the Phase 2/3 study of its mRNA respiratory syncytial virus (RSV) vaccine candidate.
mRNA-1345 is an RSV vaccine for a prefusion F glycoprotein,...
Johnson & Johnson recently announced that it will evaluate its COVID-19 vaccine against the new and rapidly spreading Omicron variant.
Specifically, Johnson & Johnson is testing blood...
GSK recently appointed Phil Dormitzer, MD, PhD, as global head of vaccines research and development and a member of the vaccines leadership team.
Previously, Dormitzer was vice president and chief...
Pfizer and BioNTech recently announced that their COVID-19 vaccine, BNT162b2, was 100 percent effective in adolescents 12 through 15 years of age in a longer-term analysis.
Researchers also...
CDC Director Rochelle Walensky, MD, MPH, recently endorsed the CDC Advisory Committee on Immunization and Practices’ (ACIP’s) recommendation for COVID-19 vaccine booster shots to include...
The US government recently purchased 10 million courses of Pfizer’s COVID-19 antiviral candidate, PAXLOVID.
Under the terms of the agreement, the government will acquire 10 million...
Pfizer, BioNTech, and instant logistics company, Zipline, collaborated to deliver authorized mRNA COVID-19 vaccines requiring ultra-cold-chain in Ghana.
The companies recently developed and...
Johnson & Johnson recently entered into an agreement with the US government and Gavi, the Vaccine Alliance, to allow access to its single-shot COVID-19 vaccine through the COVAX Humanitarian...
The US government recently purchased additional doses of Eli Lilly and Company’s combination COVID-19 antibody treatment.
Under the agreement, Eli Lilly and Company will supply 614,000 doses of...
